ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Breakthrough Designation Granted to Pfizer’s Palbociclib

April 26, 2013

Loss Of Core Grants Imperials Status Of Three Comprehensive Cancer Centers

July 14, 1989

Study: Lack of Sleep Linked With Agressive Breast Cancers

September 28, 2012

Silicone Implants Not Linked To Increased Risk Of Death

May 25, 2001

NCA Declines To Set Minimum Comp Center Bed Number

April 2, 1976

Professional Fundraiser Poses Eight Questions For SU2C 3.

September 19, 2008